Tolerability

Low rates of discontinuation due to behavioral, psychiatric, and cognitive events In monotherapy controlled clinical trials*…

Safety Tolerability

	12% of 898 adult patients discontinued due to adverse events (AEs)1 —  The most common AEs (>1%) leading to discontinuation were: rash (2.3%), nausea (1.8%), dizziness (1.7%), headache (1.4%), and somnolence (1.3%)
	3.6% of 253 pediatric patients discontinued due to AEs1 —  The most common AE (>1%) leading to discontinuation was rash (2.4%)

*Includes data from double-blind controlled studies and a rater-blind controlled study in monotherapy.

1.

Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.